PMID- 37266677
OWN - NLM
STAT- MEDLINE
DCOM- 20240221
LR  - 20240221
IS  - 1435-1250 (Electronic)
IS  - 0340-1855 (Linking)
VI  - 83
IP  - Suppl 1
DP  - 2024 Feb
TI  - Comparison of the efficacy and safety of olokizumab at different dosages in 
      patients with active rheumatoid arthritis: a network meta-analysis of randomized 
      controlled trials.
PG  - 107-114
LID - 10.1007/s00393-023-01367-w [doi]
AB  - OBJECTIVE: This study aimed to assess the relative efficacy and safety of 
      olokizumab at different dosages in patients with active rheumatoid arthritis 
      (RA). METHODS: We performed a Bayesian network meta-analysis to combine direct 
      and indirect evidence from randomized controlled trials (RCTs) to examine the 
      efficacy and safety of olokizumab administered intravenously to RA patients at 
      64 mg/kg every 2 or 4 weeks (Q2 or Q4W). RESULTS: Five RCTs comprising 
      2609 patients met the inclusion criteria. Both olokizumab Q2 and Q4W treatments 
      achieved a significant American College of Rheumatology 20% response (ACR20) 
      compared with the placebo (odds ratio [OR] 3.21, 95% credible interval [CrI] 
      2.53-4.09; OR 3.05, 95% CrI 2.43-3.86). However, olokizumab Q2W was associated 
      with the most favorable surface using the cumulative ranking curve (SUCRA) for 
      the ACR20 response rate. The ranking probability based on the SUCRA indicated 
      that olokizumab Q2W had the highest probability of being considered the best 
      treatment option for achieving the ACR20 response rate, followed by olokizumab 
      Q4W, adalimumab, and placebo. The ACR50 and 70 response rates showed a similar 
      distribution pattern to the ACR20 response rate, except that olokizumab Q4W had 
      a higher-ranking probability than olokizumab Q2W for ACR50. The SUCRA rating 
      likelihood of adverse events (AEs) and withdrawal due to AEs showed that 
      a placebo was likely to be the best intervention. CONCLUSION: Both olokizumab Q2 
      and Q4W were efficacious and well-tolerated treatments for active RA.
CI  - (c) 2023. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, 
      ein Teil von Springer Nature.
FAU - Lee, Young Ho
AU  - Lee YH
AD  - Department of Rheumatology, Korea University Anam Hospital, Korea University 
      College of Medicine, 73, Goryeodae-ro, Seongbuk-gu, 02841, Seoul, Korea (Republic 
      of). lyhcgh@korea.ac.kr.
FAU - Song, Gwan Gyu
AU  - Song GG
AD  - Department of Rheumatology, Korea University Anam Hospital, Korea University 
      College of Medicine, 73, Goryeodae-ro, Seongbuk-gu, 02841, Seoul, Korea (Republic 
      of).
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
TT  - Vergleich der Wirksamkeit und Sicherheit von Olokizumab in verschiedenen 
      Dosierungen bei Patienten mit aktiver rheumatoider Arthritis: 
      Netzwerk-Metaanalyse randomisierter kontrollierter Studien.
DEP - 20230602
PL  - Germany
TA  - Z Rheumatol
JT  - Zeitschrift fur Rheumatologie
JID - 0414162
RN  - 0 (Antirheumatic Agents)
RN  - YL5FZ2Y5U1 (Methotrexate)
RN  - PAI71R1D2W (olokizumab)
RN  - 0 (Antibodies, Monoclonal, Humanized)
SB  - IM
MH  - Humans
MH  - *Antirheumatic Agents/therapeutic use
MH  - Methotrexate/therapeutic use
MH  - Network Meta-Analysis
MH  - Treatment Outcome
MH  - Bayes Theorem
MH  - Randomized Controlled Trials as Topic
MH  - *Arthritis, Rheumatoid/diagnosis/drug therapy
MH  - *Antibodies, Monoclonal, Humanized
OTO - NOTNLM
OT  - Efficacy
OT  - Network meta-analysis
OT  - Olokizumab
OT  - Rheumatoid arthritis
OT  - Safety
EDAT- 2023/06/02 13:15
MHDA- 2024/02/21 11:15
CRDT- 2023/06/02 11:08
PHST- 2023/04/07 00:00 [accepted]
PHST- 2024/02/21 11:15 [medline]
PHST- 2023/06/02 13:15 [pubmed]
PHST- 2023/06/02 11:08 [entrez]
AID - 10.1007/s00393-023-01367-w [pii]
AID - 10.1007/s00393-023-01367-w [doi]
PST - ppublish
SO  - Z Rheumatol. 2024 Feb;83(Suppl 1):107-114. doi: 10.1007/s00393-023-01367-w. Epub 
      2023 Jun 2.